Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs TG Therapeutics Inc — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.62 (market cap $157.51B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 20.6× TG Therapeutics Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 3.8% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BBVA | TGTX | |
|---|---|---|
Market Cap | $157.51B | $7.64B |
Sector | Financials | Health |
52-Week High | $28.50 | $59.06 |
52-Week Low | $17.96 | $26.94 |
Dividend Yield | 3.8% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.545, up 0.69% today, with a bullish technical signal from moving averages but overbought RSI readings. The bank reported strong Q2 2026 earnings, beating estimates with an 11.4% net profit rise, and announced a $2.3 billion share buyback. Revenue growth has been steady, reaching $39.42 billion in 2025, with a net income margin of 26.13% and ROE of 18.5%, though valuation ratios like P/E of 12.98 and P/S of 3.27 suggest moderate pricing.
Outlook remains positive with analyst consensus at 53.85% buy ratings, driven by profitability improvements and strategic initiatives. Key risks include regulatory probes in Spain and antitrust investigations, which could impact sentiment. Investors should weigh solid fundamentals against legal uncertainties for balanced exposure.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
